Eevia needs to manufacture its significant side-streams into sellable products to be profitable on compendial products. When we process a batch of 9 tons of wild berries, we gain approximately 90 kg of high-value extract, but we also get almost 9 tons kg of side-stream materials — various fractions containing valuable polyphenols, fibers, and organic compounds. There are currently treated as biowaste at a cost. Unlocking that value as nutritional inputs for the food and health industry will increase revenues and reduce costs and significantly improve profitability and sustainability. Not doing it is unsustainable.

We are excited to work with Eevia Health in advancing their berry-based health products. Our test-plant was designed exactly for this mission—helping companies turning natural renewable resources into health and nutrition innovations.

This move provides Eevia flexibility and strategic clarity. Besides containing cost, this partnership enables us to innovate smarter and improve production protocols. We have huge commercial opportunities in the vast and fast-growing polyphenolic nutraceutical space. With BIOTEP we can immediately reduce fixed costs in Finland, while boosting sales through new customers and partners, and get the break we need to shift the company to a stronger position. Succeeding against incumbent multinational competitors with limited financial resources demands sharp strategic focus, agile execution, technology leadership, and strong financial discipline. We know how to beat competition and provide offers consumers can’t refuse, so we will fight, and we will eventually win.

By outsourcing sales, marketing, and clinical studies, Eevia can focus on manufacturing and supply chain operations. Our Partner’s investment in clinical substantiation and commercialization allows Eevia to scale this product without incurring major development costs, fuelling our revenue growth while enabling us to focus our scarce resources on other ingredients in our portfolio.

Our new partner helped us understand that Eevia has a unique category of high-strength extracts which provides multiple operational benefits for manufacturers of consumer dosages. Being excipient free, it also reduces the chance for adulteration and imposters. This partnership validates the new strategy we decided in 2024 on many levels.

The interest expressed by these potential partners is strong and compelling. The Letters of Intent confirm a clear intent to collaborate on go-to-market strategies and further validate the commercial potential of our lead pipeline products as we move toward clinical substantiation of their health benefits.

We see tariff effects converting into market traction and growing demand for our high-quality organic extracts.

The market has suddenly shifted. U.S. buyers who previously relied on Chinese suppliers are now urgently looking to Europe for which tariffs are significantly lower.

The TO2 Warrants, and a direct equity issue will help Eevia Health to exploit some significant immediate commercial growth opportunities. These equity transactions will also support ongoing efforts to achieve non-dilutive funding (R&D Loan) of c. KEUR 550 from applications we expect to get decisions on by Mid-May.

We have some exciting news to share in Barcelona — stay tuned!

This is a sophisticated customer with high standards, and securing this repeat order is a testament to the quality and reliability of our products. Moreover, this order contributes to achieving our financial turnaround targets for the first quarter of 2025—an important milestone for our team.

I appreciate the support from shareholders and investors. We are actively implementing our strategic turnaround plan, driving significant cost savings and improving cash flow through reduction of inventory and improvements in order income and sales revenues. These improvements are helping us to strengthen cash flow and meet our 2025 financial targets. While the rights issue improved our balance sheet and liquidity, it hasn't fully relieved the liquidity pressure. To address this, we are asking unsecured creditors to restructure the remaining debt and significantly extend the payment time profile. We also seek to conduct a directed equity issue for approximately SEK 4.5 million to cover part of the unsubscribed portion of the rights issue. Once we have completed these actions, we'll be stronger to achieve our 2025 and 2026 financial goals.

I am excited and confident about Eevia's future. The current Board has supported Management in carving out an ingenious and future oriented plan to target tremendous and relevant market opportunities for our core strengths. The subscription made today is my vote of strong confidence in the plan for Eevia 2.0, which leverages what we have learned to address real human health challenges supported by nature and leading nutritional science. I see a huge value upside in our venture, and hope shareholders and investors can see the same.

I am excited and confident about Eevia's future. The current Board has supported Management in carving out an ingenious and future oriented plan to target tremendous and relevant market opportunities for our core strengths. The subscription made today is my vote of strong confidence in the plan for Eevia 2.0, which leverages what we have learned to address real human health challenges supported by nature and leading nutritional science. I see a huge value upside in our venture, and hope shareholders and investors can see the same.

This partnership offers a global sales reach, with growth potential for Eevia from 2025 onward. By outsourcing clinical studies, marketing and sales, Eevia can focus on supply chain and manufacturing while our partner is driving revenue growth.

I am thrilled to join Eevia. Ultimately, the key to success is driving sales revenues. Eevia has huge global growth potential, but it needs to strengthen its sales function, build a Nordic brand, with substantiated claims on Eevia's unique products. I am ready to acquire more shares and am committed to helping the Eevia team rebuild and expand its customer base

We’re excited to expand our reach via Ingredients Online’s platform, which simplifies access to new markets, especially for food-grade powders that complement our business

We warmly welcome Baccas Salus Oy as they establish berry extract manufacturing in Kemijärvi! We will offer our full support to help ensure the company’s success with the resources at our disposal.

Eevia has developed expertise in berry extract manufacturing and identified three valuable commercial opportunities. However, its size and resources limit its ability to handle such an ambitious agenda. The core Eevia business must focus on revenue and profit, while non-dilutive funding for R&D and investments is organized separately. Each commercial opportunity needs a separate strategy for success. By offering these opportunities to Eevia's shareholders, they gain three chances for success instead of one.

We are confident in achieving revenue streams from these new proprietary high-margin gastrointestinal health solutions at the end of 2025 based on positive feedback and interest from significant brands and the confidence and excitement of our science advisors.

We welcome the approval of our bilberry extract and this new first sales order and look forward to developing the business with this great customer.

The RTO was an interesting opportunity and worth investigating, but the decision is clear. Eevia can now put full attention and resources to its new strategic business plan, which the newly elected Board endorsed on November 6 and now has re-endorsed. The immense opportunities and prospects of Eevia’s Arctic polyphenol products within the gut health and adjacent health areas constitute a path to significant revenue growth and value creation for our Company.

Polyphenols such as proanthocyanidins can play a huge role in human health. Polyphenols have been marginalized as a component in our modern processed food compared to what our ancestors would take in through a more plant-heavy diet. We aim to compete by providing health solutions consumers can benefit from with the highest-quality polyphenol extracts and blends in the market.

We are extremely excited to welcome Dr. Clayton to the Board of Directors of Eevia Health. She has already advised us on gut health strategies, and we have experienced the wealth of knowledge and personal network she has that is directly relevant to the business plans we have for Eevia.

It is necessary for Eevia Health to receive external non-dilutive funding to progress the Retinari™ project, which is a game-changing eye health prophylactic, towards market launch. Eevia is working to secure other supplemental funding options, including commercial partners, to strengthen the initiation of the safety study. Other than funding, we are immediately ready to proceed with the project. The product has huge societal, individual, and commercial impact potential.

We see a spike in the interest for Feno-Chaga organic, and it is a product with good profitability for us, so we are especially pleased to see conversion to sales orders for this SKU. Dietary supplements based on mushrooms are growing fast in key markets. Various agencies estimate 10 to 15% growth (CAGR 2025 -2030) for mushroom-derived products. Chaga is known as the “King of Mushrooms". Feno-Chaga is one product we have conducted a human clinical trial on with interesting results for stress management and sports performance.

This is quite a big breakthrough for Eevia, which will significantly impact our product profitability on berry extracts. So far, these volumes have been going to wastewater and have been only costs for us. With these efforts, we will be able to create revenues with low effort and low additional costs. Furthermore, the pilot customer was already impressed with the samples' quality and indicated readiness to take several hundred tons per year. For every 1,000 tons of berries we consume for extract manufacturing, we will be able to produce 100-150 tons of the liquid sugar concentrates

I’m grateful for the vote of confidence in our Company from our current and new investors. The rights issue funds are essential pillars in our financial growth plan. Eevia plans to take advantage of several great market opportunities. The board and the management team focus on our financial targets and revenue growth. I look forward to communicating our progress with you going forward.

I’m grateful for the vote of confidence in our Company from our current and new investors. The rights issue funds are essential pillars in our financial growth plan. Eevia plans to take advantage of several great market opportunities. The board and the management team focus on our financial targets and revenue growth. I look forward to communicating our progress with you going forward.

I’m grateful for the vote of confidence in our Company from our current and new investors. The rights issue funds are essential pillars in our financial growth plan. Eevia plans to take advantage of several great market opportunities. The board and the management team focus on our financial targets and revenue growth. I look forward to communicating our progress with you going forward.

First-order sales of new products are milestones. It is a significant start sale for our tart cherry product, which we expect will open the gates for other brands. It is a long-sought win with an extremely fastidious customer. The customer is excited about the quality and strength of this product. One can see the difference in quality from competitor’s products with the naked eye – our product's dark, vibrant red color exudes potency.

This opportunity will provide scientific substantiation on our ingredient funded by our partner and a global sales and distribution reach for this ingredient. The partnership has interesting growth potential for Eevia’s revenues from 2025 onward without major expenses by Eevia in 2024 or 2025. By outsourcing this ingredient's clinical substantiation, marketing, sales, and distribution, Eevia Health can focus its limited resources on other extract products in its portfolio and, for this ingredient, supporting our partner on the supply chain and manufacturing. Our partner will be able to scale up the sales volume of this product, which will benefit our overall revenue growth.

One step at a time we move towards addressing a significant global health problem. This is a big step with potential for significant business revenue growth and societal impact.

This is an important sale and an indication of our potential. After a lengthy sales process, Eevia has established a new, larger and sophisticated customer who will increase our distribution and visibility in the market. A great win for our Team

By being in this ecosystem led by Valio, Eevia could identify possible applications for our products and side streams in food and beverage sector. We expect this partnership to open new, interesting avenues for our future R&D activities as well.

"We are very happy to see our Australian distributor succeed in this product group and pleased to see that our European Elderberry extracts succeed in competition with other less bioactive extracts in the Far Eastern markets."

The BioMAP comparison of our pine bark extract against the market leader is compelling and confirms that our product is nearly identical in vitro bioactivity to the market leader. Substantiating bioactivity in human primary cells can support sales traction and order updates from the marketplace.

We achieved remarkable results on our eye-health ingredient in the Eurofins BioMAP in-vitro assay system employing over 140 biomarkers. The data strengthened the case for possible clinical efficacy in maintaining homeostasis of Retinal Pigment Epithelium cells (RPE cells) in the human eye. This brings us closer to the market launch of a novel and effective pre-treatment for macular degeneration to a EUR 5 billion eye-health segment utilizing Finnish circular raw materials and pharmacology competencies to drive an ophthalmologic health innovation that provides eye health protection, improves patient care outcomes, and reduces costs to the health system.

We were in 2022 criticized by some investors for offering too little information related to sales orders, so we lowered the threshold to KEUR 10. Lately, we have been criticized for informing about too small orders. After contemplating this, we have raised the threshold to KEUR 50 for informing about sales orders.

The BioMAP study provided unique bioactivity data on our key extracts, which strengthen our competitive position in selected nutraceutical segments.

This opportunity fits our strategy to build the business on our basic ingredients, while we develop proprietary novel prophylactic nutritional solutions addressing significant global health problems.

Eevia had a transformative 2023 where we broadened our customer base and laid the foundation for strong growth in the years to come. The credit line provides for short-term working capital to continue with our strategic focus on expanding the business.

Although we were in contact some years ago, before Covid, we see this as the first order from this customer. Although the order is small, we are excited, because the contract manufacturer serves several large brands, and our pine bark extract has the potential to compete well. The customer is excited in general about our polyphenol products, and we expect further orders during 2024.

It is the first order from this customer. Although the order is small, we are a bit excited, because the business came via one very well-known independent product formulator, who is kind of an “industry influencer”, and who formulates products for several large brands. We first met him in Las Vegas in October 2023, so the sales cycle was not that long. He is excited about our polyphenol products and may include our ingredients in products for other brands.

This project is a welcome opportunity for Eevia to lock in significant revenues for 2025, and potentially for 2026 and 2027. This and similar opportunities we have in our pipeline provide traction towards achieving our long-term revenue target of EUR 25 million

We are excited to get these orders because it is a promising start to the marketing and sale of our side stream products. It constitutes a welcome upcycling development which will impact our profitability and further our industry-leading sustainability status.

The ability to offer FOB prices from New Jersey will make Eevia more competitive in the North American market. It will support our partners in North America to improve our value proposition in terms of rapid response and reliability of supply, while we reduce logistical costs.

We are happy to do the “maiden shipment” under this new supply-chain arrangement. We believe keeping buffer stock in the US with ready imported materials with all certificates issued including the USDA NOP certificate for organic products, will provide better customer service and improved ability to serve smaller orders.

We warmly welcome Erik to this new role. His strong experience in solution sales and nutraceuticals in the international environment, has led to success in his previous roles. Erik brings a deep understanding of how companies work on operational and executive levels, and how to create value for customers. He will contribute significantly to the success and global growth of Eevia and we are extremely pleased with him joining our team.

The post-covid market is evolving and we are adapting. We have now significant interest in the North American market